ANTITHROMBOTIC THERAPY IN PATIENTS WITH VALVULAR HEART DISEASE: WHAT'S NEW?

The article presents an overview of modern data and an analysis of the recommendations of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery published in 2017 regarding the use of antithrombotic therapy in patients with valvular heart disease. The results of studies devoted to the use of new oral anticoagulants in patients with valvular heart disease are demonstrated.

heart defects, valvular heart disease, valvular pathology, atrial fibrillation, mitral stenosis, mitral regurgitation, aortic regurgitation, aortic stenosis, warfarin, vitamin K antagonists, new oral anticoagulants, rivaroxaban, apixaban, dabigatran, edoxaban, ablation

1. Рекомендации РКО, ВНОА, АССХ. Диагностика и лечение фибрилляции предсердий. Российский кардиологический журнал 2013;4(приложение 3): 1–100.

2. Di Pasquale G., Zagnoni S., Riva L. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated? Intern Emerg Med 2015;10(1):21–4. DOI: 10.1007/s11739-014-1181-5.

3. Breithardt G., Baumgartner H., Berkowitz S.D. et al. ROCKET AF Steering Committee and Investigators. Clinical characteristics and outcomes with rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation but underly ing native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35(47):3377–85. DOI: 10.1093/eurheartj/ehu305.

4. Avezum A., Lopes R.D., Schulte P.J. et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation 2015;132(8): 624–32. DOI: 10.1161/CIRCULATIONAHA.114.014807.

5. Ezekowitz M.D., Nagarakanti R., Noack H. et al. Comparison of dabigatran and warfarin in patients with atrial fibrilla tion and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation 2016;134(8):589–98. DOI: 10.1161/CIRCULATIONAHA.115.020950.

6. Baumgartner H., Falk V., Bax J.J. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38(36):2739–91. DOI: 10.1093/eurheartj/ehx391.

7. Фибрилляция и трепетание предсердий у взрослых. Клинические рекомендации 2016 г. Доступно по: http:// cr.rosminzdrav.ru/schema.html?id=888#/ text. [Fibrillation and atrial flutter in adults. Clinical recommendations 2016. Available at: http://cr.rosminzdrav.ru/ schema.html?id=888#/text. (In Russ.)].

8. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37(38):2893–962. DOI: 10.1016/j.rec.2016.11.033.

9. Butchart E.G., Gohlke-Barwolf C., Antunes M.J. et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005;26(22):2463–71. DOI: 10.1093/eurheartj/ehi426.

10. Laffort P., Roudaut R., Roques X. et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol 2000;35(3):739–46. PMID: 10716478.

11. Heneghan C., Ward A., Perera R. et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379(9813):322–34. DOI: 10.1016/S0140-6736(11)61294-4.

12. Bussey H.I., Bussey M., Bussey- Smith K.L., Frei C.R. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin K with genomic considerations: a pilot study. Pharmacotherapy 2013;33(11):1136–46. DOI: 10.1002/phar.1343.

13. Massel D.R., Little S.H. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013;7:CD003464. DOI: 10.1002/14651858.CD003464.pub2.

14. Kristensen S.D., Knuuti J., Saraste A. et al. 2014 ESC/ESA Guidelines on noncardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2014;31(10):517–73. DOI: 10.1097/ EJA.0000000000000150.

15. Lancellotti P., Pibarot P., Chambers J. et al. Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the InterAmerican Society of Echo cardiography, and the Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016;17(6):589–90. DOI: 10.1093/ehjci/jew025.

16. Karthikeyan G., Senguttuvan N.B., Joseph J. et al. Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies. Eur Heart J 2013;34(21):1557–66. DOI: 10.1093/eurheartj/ehs486.

17. Laplace G., Lafitte S., Labeque J.N. et al. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients. J Am Coll Cardiol 2004;43(7):1283–90. DOI: 10.1016/j.jacc.2003.09.064.

18. Brown M.L., Park S.J., Sundt T.M., Schaff H.V. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac Cardiovasc Surg 2012;144(1):108–11. DOI: 10.1016/j.jtcvs.2011.05.032.

19. Mylotte D., Andalib A., Theriault-Lauzier P. Transcatheter heart valve failure: a systematic review. Eur Heart J 2015;36(21): 1306–27. DOI: 10.1093/eurheartj/ ehu388.